- Previous Close
1.9500 - Open
1.9400 - Bid --
- Ask --
- Day's Range
1.9200 - 2.0000 - 52 Week Range
0.4100 - 9.9300 - Volume
74,721 - Avg. Volume
180,827 - Market Cap (intraday)
53.097M - Beta (5Y Monthly) 1.99
- PE Ratio (TTM)
-- - EPS (TTM)
-1.2000 - Earnings Date Sep 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
23.23
Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer's disease. In addition, the company is developing a monoclonal antibody PBD-C06 is for N3pE-Abeta. Vivoryon Therapeutics N.V. has a collaboration agreement with Nordic Bioscience for the clinical development of PQ912 for Alzheimer's disease; and research collaboration with the Fraunhofer Institute for cell therapy and immunology, as well as a strategic regional licensing partnership with Simcere Pharmaceutical Group Ltd. to develop and commercialize medicines targeting the neurotoxic amyloid species N3pE (pGlu-Abeta) to treat Alzheimer's disease. Vivoryon Therapeutics N.V. was founded in 1997 and is headquartered in Halle, Germany.
www.vivoryon.comRecent News: VVY.AS
View MorePerformance Overview: VVY.AS
Trailing total returns as of 11/27/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VVY.AS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VVY.AS
View MoreValuation Measures
Market Cap
50.83M
Enterprise Value
35.49M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.64
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-62.86%
Return on Equity (ttm)
-112.35%
Revenue (ttm)
-3.62M
Net Income Avi to Common (ttm)
-31.18M
Diluted EPS (ttm)
-1.2000
Balance Sheet and Cash Flow
Total Cash (mrq)
15.27M
Total Debt/Equity (mrq)
0.07%
Levered Free Cash Flow (ttm)
-12.25M